A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

HR. 1432, Preserve Access to Affordable Generics Act (settlements) 3/07 S. 316, Preserve Access to Affordable Generics Act (settlements) 3/07 S. 445, Patent Reform Act HR 1908, Patent Reform Act S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 438, Fair Prescription Drug Competition Act (ban authorized generics) 1/07 HR 780, Counterfeit Drug Prevention Act of 2007 3/07 HR 1908, Patent Reform Act of 2007 S 1145, Patent Reform Act of 2007 S 623, Access to Life-Saving Medication Act (FOBS) 2/07 HR 1038, Access to Life-Saving Medication Act HR 5629, Pathway For Biosimilars Act

Client expense: $2,800,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)

HR 1432, Preserve Access to Affordable Generics Act (settlements) S 316, Preserve Access to Affordable Generics Act (settlements) S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 438, Fair Prescription Drug Competition Act (ban authorized generics) HR 780, Counterfeit Drug Prevention Act of 2007 HR 1908, Patent Reform Act of 2007 S 1145, Patent Reform Act of 2007 S 623, Access to Life-Saving Medication Act (FOBS) HR 1038, Access to Life-Saving Medication Act

Client expense: $7,220,000 · Firm income: Not reported

S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical countefeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 3010, Department of Labor, Health and Human Service, and Education, and Related Agencies Appropriations Act, 2006, access to prescription drugs HR 3971, Social Services Emergency Relief and Recovery Act of 2005, access to prescription drugs HR 5993, Authorized Generics Prohibition, authorized generics S 3695, Authorized Generics Prohibition, authorized generics HR 4157, Better Health Information System Act, health information technology HR 4642, Wired for Health Act, health information technology S 1418, Wired for Health Act, health information technology S 2300, Lower Priced Drug Act, generic drug access HR 5005, Ryan White Care Act, reauthorization S 2339, Ryan White Care Act, reauthorization HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

Client expense: $6,000,000 · Firm income: Not reported

S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 3010, Department of Labor, Health and Human Service, and Education, and Related Agencies Appropriations Act, 2006, access to prescription drugs HR 3971, Social Services Emergency Relief and Recovery Act of 2005, access to prescription drugs HR 5993, Authorized Generics Prohibition, authorized generics S 3695, Authorized Generics Prohibition, authorized generics HR 4157, Better Health Information System Act, health information technology S 2300, Lower PRICED Drug Act, generic drug access, legislation on pediatric exclusivity, citizens petitions HR 6134, Ryan White Care Act, reauthorization S 2339, Ryan White Care Act, reauthorization HR 5975, Prescription Drug Comparative Effectiveness Act, drug prescriptions S 1355, Better Healthcare Through Information Technology Act, health information technology HR 6289, Personalized Health Information Act of 2006, health information technology HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

Client expense: $5,800,000 · Firm income: Not reported

HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, imporation, patent issues S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To Amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To amend title 35, United States Code, to conform certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 3818, Patent Reform Act of 2006 S 3175, Life-Saving Medicines Export Act of 2006, compulsory licensing S 3834, Online Pharmacy Consumer Protection Act of 2006, prescription drugs S 1903, Generic Prescription Drug Fairness Act of 2005, authorized generics and rebates

Client expense: $5,800,000 · Firm income: Not reported

S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 3010, Department of Labor, Health and Human Service, and Education, and Related Agencies Appropriations Act, 2006, access to prescription drugs HR 3971, Social Services Emergency Relief and Recovery Act of 2005, access to prescription drugs HR 5993, Authorized Generics Prohibition, authorized generics S 3695, Authorized Generics Prohibition, authorized generics HR 4157, Better Health Information System Act, health information technology S 2300, Lower PRICED Drug Act, generic drug access, legislation on pediatric exclusivity, citizens petitions HR 6134, Ryan White Care Act, reauthorization S 2339, Ryan White Care Act, reauthorization HR 5975, Prescription Drug Comparative Effectiveness Act, drug prescriptions S 1355, Better Healthcare Through Information Technology Act, health information technology HR 6289, Personalized Health Information Act of 2006, health information technology HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

Client expense: $7,720,000 · Firm income: Not reported

HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, imporation, patent issues S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To Amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To amend title 35, United States Code, to conform certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 3818, Patent Reform Act of 2006 S 3175, Life-Saving Medicines Export Act of 2006, compulsory licensing S 3834, Online Pharmacy Consumer Protection Act of 2006, prescription drugs S 1903, Generic Prescription Drug Fairness Act of 2005, authorized generics and rebates

Client expense: $7,720,000 · Firm income: Not reported

H.R. 5122-Defense Authorization Bill-re price control issues. S.2766-Defense Authorization Bill- re price control issues. Prescription Drug User Fee Act issues. S.3695, Food, Drug, & Cosmetic Act amendments, provisions regarding authorized generic drugs and the 180 day exclusivity period; S.2300,Lower Priced Drug Act, provisions relating to 180 day exclusivity regarding period pediatric studies.

Client expense: $1,380,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 2345 Counterfeit Drug Enforcement Act of 2005 H.R. 4829 Reducing Fruadulant and Imitation Drug Act of 2005: S. 2300 Lower PRICED Drug Act. Meetings with Members of Congress regarding generic biologics and Food and Drug Administration regulatory activity of interest to the Registrant. Various bills regarding the importation of prescription drugs including: H.R. 328, S. 109, H.R. 700, S. 334. H.R. 753, and S. 184. H.R. 5993, S. 3695: legislation to prohibit the marketing of authorized generic drugs.

Client expense: $440,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 3175, Life-Saving Medicines Export Act of 2006. H.R. 6257, Access to Life-Saving Medicine Act. S. 4016, Access to Life-Saving Medicine Act. Matters relating to the Best Pharmaceuticals for Children Act reauthorization and Pediatric Research Equity Act reauthorization. Matters relating to the Prescription Drug User Fee Act reauthorization. S. 3695, A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs. H.R. 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs. S. 3981, Citizen Petition Fairness and Accuracy Act of 2006. S. 2300, Lower PRICED Drugs Act. H.R. 6022, Lower PRICED Drugs Act. H.R. 5533, Biodefense and Pandemic Vaccine and Drug Development Act of 2006. S. 2564, Biodefense and Pandemic Vaccine and Drug Development Act of 2006, Sec. 5.

Client expense: $680,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

S. 3981, the Citizen Petition Fairness and Accuracy Act Abbreviated New Drug Application No. 76-396 for calcitonin-salmon nasal spray Hatch-Waxman Amendments S. 3582, the Preserve Access to Affordable Generics Act S. 3695, HR. 5993, to prohibit Authorized Generics during 180 day exclusivity HR 6257 & S. 4016, the Access to Life Saving Medicines Act S. 2300 & HR 6022, the Lower Priced Drugs Act

Client expense: $102,200 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006

Client expense: $713,336 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)